Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Naylor

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Annals of the New York Academy of Sciences|January 1, 1984
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunctionP H Naylor, R S Schulof, M B Sztein, et al.
International Journal of Immunopharmacology|January 11, 1991
Effects of PCB (Aroclor 1254) on non-specific immune parameters in rhesus (Macaca mulatta) monkeysH Tryphonas, M I Luster, K L White, et al.
AIDS Research and Human Retroviruses|August 1, 1992
A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjectsJ O Kahn, D P Stites, J Scillian, et al.
International Journal of Immunopharmacology|January 11, 1991
Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLHP H Naylor, M B Sztein, S Wada, et al.
Journal of Viral Hepatitis|July 17, 2001
African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than CaucasiansJ L Kinzie, P H Naylor, M G Nathani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infectionJ D Jiang, F N Chu, P H Naylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1990
Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of actionC N Conteas, M G Mutchnick, K C Palmer, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Annals of the New York Academy of Sciences|January 1, 1984
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunctionP H Naylor, R S Schulof, M B Sztein, et al.
International Journal of Immunopharmacology|January 11, 1991
Effects of PCB (Aroclor 1254) on non-specific immune parameters in rhesus (Macaca mulatta) monkeysH Tryphonas, M I Luster, K L White, et al.
AIDS Research and Human Retroviruses|August 1, 1992
A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjectsJ O Kahn, D P Stites, J Scillian, et al.
International Journal of Immunopharmacology|January 11, 1991
Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLHP H Naylor, M B Sztein, S Wada, et al.
Journal of Viral Hepatitis|July 17, 2001
African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than CaucasiansJ L Kinzie, P H Naylor, M G Nathani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infectionJ D Jiang, F N Chu, P H Naylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1990
Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of actionC N Conteas, M G Mutchnick, K C Palmer, et al.
Pageof 7